Crinetics price target lowered to $96 from $105 at Citizens

Citizens lowered the firm’s price target on Crinetics (CRNX) to $96 from $105 and keeps an Outperform rating on the shares. Commentary on the Palsonify launch was consistent with management’s January preannouncement while the pipeline execution continues at a steady pace, the analyst tells investors in a research note.